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Background.The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) is unclear.
Methods. We conducted a systematic review and meta-analysis of randomized controlled trials evaluating risk of adverse events
in participants receiving different durations of DAPT following insertion of drug-eluting stents. Results. Five trials were included,
but only four had data suitable for meta-analysis (𝑛 = 8, 231 participants). No significant increase in the composite endpoint of
death and nonfatal myocardial infarction was observed with earlier cessation of DAPT in any instance when compared to longer
durations of DAPT (RR 0.64 95% CI 0.25–1.63 for 3 versus 12 months, RR 1.09 95% CI 0.84–1.41 for 6 versus 12 months and, RR
0.64 95% CI 0.35–1.16 for 12 versus 24 months). Pooled results showed a significantly lower risk of major bleeding (RR 0.48 95%
CI 0.25–0.93) and total bleeding (RR 0.30 95% CI 0.16–0.54) for shorter compared to longer duration of DAPT. Subgroup analysis
based on age, prior diabetes, and prior ACS failed to show any group where longer durations were consistently better than shorter
ones. Conclusions. There are no cardiovascular or mortality benefits associated with extended duration of DAPT, but the risk of
major bleeding was significantly lower with shorter lengths of therapy.
1. Introduction
Concerns over the possibility of early coronary stent throm-
bosis have led to calls for longer durations of dual antiplatelet
therapy (DAPT) following drug-eluting stent implantation.
Whilst prolonged courses of therapy may possibly reduce the
risk of thrombotic complications, this strategy is offset by
the risk of bleeding complications. Clinical guidelines vary
between North America and Europe. The American Heart
Association/American College of Cardiology recommend
that clopidogrel and aspirin therapy should be extended to
at least 12 months after DES implantation if patients are not
at high risk of bleeding [1]. Conversely the European Society
of Cardiology recommends 6 to 12 months of DAPT for
patients following elective PCI and DES implantation or 12
months in acute coronary syndromes [2]. These guidelines
are largely based on observational studies which show that
early discontinuation of clopidogrel therapy is predictive of
stent thrombosis [3–5]. One prospective cohort study of 2,229
patientswho had receivedDES found that 29%of participants
who discontinued antiplatelet therapy prematurely had a
thrombotic event [5]. Another observational study compared
patients who had discontinued clopidogrel therapy at 6
months to those who continued therapy and a 3% of increase
in death and 4% of increase in MI or death were associated
with discontinuation of therapy [6].
Since these observational studies were performed, several
randomized controlled trials have been conducted to address
this question [6–10]. A recent meta-analysis was performed
byCassese et al. which summarized the findings of these trials
[11]. However, this meta-analysis did not explicitly present
results according to differences in cutoff time for duration of
DAPT. The reviewers did not look at consistency of findings
across different patient groups (such as the elderly or those
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with diabetes mellitus), and the meta-analysis may have
lacked power overall because it considered only specific indi-
vidual endpoints rather than a composite of clinically impor-
tant adverse events such as death or myocardial infarction.
The aim of our study is to perform a meta-analysis of
high quality randomized controlled trials that evaluated risk
of mortality and thrombotic events associated with different
durations of DAPT after PCI with drug-eluting stents.
2. Methods
2.1. Eligibility Criteria. We selected parallel group random-
ized controlled trials involving dual antiplatelet therapy
(aspirin plus any of the following agents: clopidogrel or ticlo-
pidine or prasugrel or ticagrelor) for a specified duration
following coronary stenting with the comparator arm being
dual antiplatelet therapy for a different duration. While the
main focus was on patients treated with drug-eluting stents,
we also accepted trials that had a mixture of patients with
bare metal and drug-eluting stents. We excluded trials that
compared different stents, or different antiplatelet agents
rather than different durations of antiplatelet therapy after
coronary stenting.
2.2. Search Strategy. We searched MEDLINE and EMBASE
through OvidSP using the Haynes optimized search strategy
(Health Information Research Unit, McMaster University)
[12]. The exact search strategy is shown in Appendix 1 (see
Appendix 1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2014/794078). We also checked the
bibliographies of included trials for any relevant studies. In
addition, we used the PubMed automated updates for new
articles up to August 2013.
2.3. Study Selection and Data Abstraction. Two reviewers
(CSK and HB) independently and in duplicate assessed
titles and abstracts and excluded those that were clearly
not relevant. The reviewers then went on to obtain full-text
versions of potentially suitable articles for detailed evaluation
against the eligibility criteria.
Following discussion and full agreement on the included
and excluded studies, the two reviewers independently
extracted data from relevant studies. The data extraction was
then checked by the other authors (YKL and ADR) and
full consensus was reached after resolving any discrepancies
through discussion and further review of the manuscripts.
Our primary outcome of interest was a composite of all-
cause death and nonfatal myocardial infarction.We also con-
sidered individual endpoints ofmyocardial infarction, stroke,
cardiovascular death, all-cause mortality, stent thrombosis,
and need for revascularization.
We aimed to evaluate adverse events including throm-
bolysis in myocardial infarction major bleeding, as well
as specific subcategories of gastrointestinal bleeding and
intracranial hemorrhage.
2.4. Study Characteristics and Quality Assessment. Two
reviewers (CSK and HB) extracted data on study character-
istics, which was then checked by the other reviewers (AR
and YKL). We recorded the study design, duration of DAPT
exposure, number of participants, duration of followup,
outcomes evaluated, outcome events, PCI procedural data,
angiogram results, patient selection criteria, compliance with
medication, and doses of antiplatelet used in the RCTs.
Quality assessment was conducted based on the rec-
ommendations of the Cochrane handbook of systematic
reviews [13] which included consideration of randomization
sequence generation, allocation concealment, blinding of
participants, personnel and outcome, incomplete or selective
outcome reporting, and publication bias. We aimed to pro-
duce a funnel plot if there were >10 included studies with no
evidence of statistical heterogeneity.
2.5. Quantitative Data Synthesis. RevMan 5.021 (Nordic
Cochrane Center) was used to conduct fixed-effect meta-
analysis for the pooled relative risks (RR), with 95% confi-
dence intervals for dichotomous outcomes.Themain analysis
was on an intention to treat basis, and all reported𝑃 values are
two-sided, with significance set at 𝑃 less than 0.05. Statistical
heterogeneity was assessed using 𝐼2 statistic, with 𝐼2 values of
30–60% representing a moderate level of heterogeneity [14].
We aimed to perform prespecified subgroup analysis
based on nature and duration of antiplatelet therapy, type of
stent, and specific patient populations such as the elderly or
those with diabetes mellitus. Risk ratios were pooled using
the inverse variance method for specific patient subgroups in
the trials.
3. Results
3.1. Study Selection, Design, and Methodology. Five studies
met the inclusion criteria (4 open label RCTs [6–9] and 1
double-blind RCT [10]) and the process of study selection is
shown in Figure 1. Four studies were included in the meta-
analysis as one of the studies (presented as a conference
abstract) provided insufficient information to allow detailed
quantitative evaluation.
The four trials included a total of 8,231 participants and
these trials were based in South Korea and Italy between 2006
and 2010.The definition of short and long duration of studies
varied from 3 to 12 months for the shorter duration and from
12 to 36months for the longer duration andparticipants in the
trials were followed up for up to 2 years. One trial compared 3
months versus 12 months, two compared 6 months versus 12
months, and one trial evaluated 12 months versus 24 months.
While all the trials compared aspirin and clopidogrel, the
dose was consistent at 75mg for clopidogrel across all trials
but the dose of aspirin varied from 100 to 200mg. The
types of stents used varied among the trials, but they all
used one or more of the following stents: everolimus-eluting
stent, sirolimus-eluting stent, Endeavor zotarolimus-eluting
stent, Resolute zotarolimus-eluting stent, paclitaxel-eluting
stents, and bare metal stent. All four studies reported stent
thrombosis,myocardial infarction/acute coronary syndrome,
all-cause mortality, and major bleeding event.
These studies along with the design, year of study, def-
inition of short and long duration, total number of partic-
ipants in each group, duration of follow-up, and outcomes
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Figure 1: Flow diagram of study selection (from [15, 16]).
evaluated are shown in Table 1.The patient’s selection criteria
and demographics, comorbidities, angiography results, PCI
procedural information, study outcomes, and compliance
with medications are shown in Appendices 3–7. The rates of
thrombotic events and bleeding events are shown in Tables 2
and 3, respectively.
3.2. Quality Assessment. The quality of studies is shown in
Appendix 2. Randomization was considered adequate for
most trials, but some degree of loss to follow-up was noted.
Although the four studies included in the meta-analysis
were open-label, the adverse events were independently
adjudicated by blinded observers.
We did not test for publication bias as there were too few
trials, but our search does include conference abstracts which
reduces the risk of publication bias.
3.3. Pooled Analysis of Death and Nonfatal Myocardial Infarc-
tion for Shorter as Compared to Longer Duration of DAPT.
For the composite measure of all-cause mortality or nonfatal
MI (Figure 2), no significant increase in risk with shorter
DAPT duration was observed for the study comparing 3
versus 12 months (RR 0.64 95% CI 0.25–1.63), two studies
of 6 versus 12 months (pooled RR 1.09 95% CI 0.84–1.41),
and one study of 12 versus 24 months (RR 0.64 95% CI
0.35–1.16). Overall, the pooled risk ratio for mortality or
nonfatal myocardial infarction with shorter DAPT across
the four trials was 0.97 (95% CI 0.77–1.22). We found
little statistical heterogeneity between trials (𝐼2 = 18%).
Although the trials varied in their cut-off time for DAPT
discontinuation, subgroup testing did not demonstrate any
significant differences (𝑃 = 0.18) in the results of the three
datasets when stratified according to duration of DAPT.
3.4. Pooled Analysis of Risk of Thrombotic Events or Mortality
for Shorter as Compared to Longer Duration of DAPT. The
results for the pooled risks of stent thrombosis, myocardial
infarction, stroke revascularization, cardiovascular death,
and overall mortality are shown in Figure 3. Again, subgroup
testing did not demonstrate any significant differences in the
results of individual endpoints from the three datasets when
stratified according to duration of DAPT.
3.5. PooledAnalysis of Risk of Bleeding for Shorter as Compared
to Longer Duration of DAPT. There was a significantly
reduced risk of major bleeding with early discontinuation
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Table 1: Study design, duration of dual antiplatelet therapy, follow-up, and outcomes evaluated.
Study ID
Design; year
of study;
country
Definition
of short and
long
duration
Total
number in
short
duration
group
Total
number in
longer
duration
group
Follow-up
duration Outcomes evaluated
Gwon et al.
2012
(EXCEL-
LENT trial)
[6]
Open-label
RCT; June
2008–July
2009; South
Korea.
Short: 6
months.
Long: 12
months.
722 721 1 year afterindex PCI.
Primary: target vessel
failure—composite of cardiac
death, myocardial infarction, or
target vessel revascularization.
Secondary: death from any cause;
death or myocardial infarction;
stent thrombosis; major bleeding;
major adverse cardiocerebral
events—composite of death,
myocardial infarction,
cerebrovascular accident, or any
revascularization; safety
endpoint—composite of death,
myocardial infarction,
cerebrovascular accident, stent
thrombosis, or thrombolysis In
myocardial infarction major
bleeding.
Hu and Wang
2012 [10]
Double-blind
RCT;
September
2008–
October 2011;
China.
Short: 12
months.
Long: >36
months.
88 94 3 years afterPCI.
Primary (12 months onwards):
target vessel failure, defined as
target vessel-related cardiac
death or myocardial infarction
and target vessel
revascularization.
Secondary outcomes included
stent thrombosis.
Kim et al.
2012 (RESET
trial) [7]
Open-label
RCT; April
2009–
December
2010; South
Korea.
Short: 3
months.
Long: 12
months.
1,059 1,058 1 year.
Primary: cardiovascular death,
myocardial infarction, stent
thrombosis, ischemia driven
target vessel revascularization,
bleeding.
Secondary: individual
components of primary endpoint
plus nontarget vessel
revascularization,
cerebrovascular accident.
Park et al.
2010
(REAL-LATE
and
ZEST-LATE)
[8]
Open-label
RCT; July
2007–
September
2008; South
Korea.
Short: 12
months.
Long: 24
months.
1,344 1,357
Median
duration of
follow-up 19.2
months after
randomization.
Primary: (12 months onwards)
myocardial infarction or death
from cardiac causes.
Secondary: death from any
cause; myocardial infarction;
cerebrovascular accident; stent
thrombosis; repeated
revascularization; a composite of
myocardial infarction or death
from any cause; a composite of
myocardial infarction,
cerebrovascular accident, or
death from any cause; a
composite of myocardial
infarction, cerebrovascular
accident, or death from cardiac
causes; and major bleeding.
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Table 1: Continued.
Study ID
Design; year
of study;
country
Definition
of short and
long
duration
Total
number in
short
duration
group
Total
number in
longer
duration
group
Follow-up
duration Outcomes evaluated
Valgimigli et
al. 2012
(PRODIGY)
[9]
Open-label
RCT;
December
2006–
December
2008; Italy.
Short: 6
months.
Long: 24
months.
983 987 2 years.
Primary: 30-day to 24-month
incidence of death from any
cause, nonfatal myocardial
infarction, or cerebrovascular
accident.
Secondary: each component of
primary outcome, cardiovascular
death, the incidence of stent
thrombosis, and bleeding
outcomes.
of antiplatelet therapy comparing 6 and >12 months (RR
0.40 95% CI 0.18–0.91) (Figure 4). The pooled result showed
significantly lower risk of major bleeding (RR 0.48 95% CI
0.25–0.93) for shorter versus longer duration, with no sig-
nificant differences found amongst the subgroups stratified
according to duration of DAPT. A significantly lower risk of
total bleeding was observed in the comparison of 6 versus 12+
months (RR 0.24 95% CI 0.12–0.50) and in the pooled results
across all four trials (RR 0.30 95% CI 0.16–0.54).
3.6. Risk of Adverse Outcomes with Specified Subgroup with
Continued andDiscontinued AntiplateletTherapy. The results
of additional subgroup analyses for three trials are shown in
Figure 5. Here, the adverse primary outcome (as specified by
trial investigators) for all participants as well as subgroups
of participants was analyzed from three of the trials that
provided relevant data. The risk of adverse outcomes with
shorter duration of DAPT did not differ significantly in
subgroups of patients with age >65 years (RR 1.03 95% CI
0.80–1.33) or those with age <65 years (RR 0.97 95% CI 0.65–
1.43). Although one trial found that the subgroup of patients
with diabetes mellitus appeared to have a significantly greater
risk of adverse outcomes with shorter DAPT [6], this finding
was not replicated in the other two trials [7, 9]. Overall, there
was no robust evidence of significantly increased or decreased
risk of adverse outcomes with DAPT in those with or without
diabetes mellitus, with moderate to substantial heterogeneity
detected (𝐼2 > 50% in the analyses). For the subgroup of
patients with prior acute coronary syndrome or unstable
disease, no significant difference in rates of adverse primary
outcomeswas observed between shorter and longer durations
of DAPT (RR 1.10 95% CI 0.83–1.45). Test for subgroup
difference (𝑃 = 0.98) amongst all the above-mentioned
patient categories did not identify any subset where shorter
duration of DAPTwas associated with significantly more risk
of adverse outcomes.
3.7. Additional Consideration of Study by Hu and Wang. One
study by Hu et al. was not included in the pooled analysis,
but its findings are consistent with those of our meta-analysis
[10]. This trial of 216 participants in China randomized
patients to 12 months or ≥36 months of dual antiplatelet
therapy and found that there was no difference between the
groups formortality,myocardial infarction, stent thrombosis,
or composite outcomes.
4. Discussion
The optimal duration of DAPT after DES implantation is a
balance between the thrombotic and hemorrhagic risks. Our
analysis of randomized data demonstrates that extending the
period of DAPT does not significantly reduce the risk of
thrombotic harm and mortality when compared to shorter
durations following PCI with drug-eluting stents. Overall,
the upper bounds of the 95% confidence interval for relative
risk of death or nonfatal MI with shorter durations were
1.22, indicating that patients are unlikely to face an increased
risk beyond 22% as compared to longer durations of DAPT.
The risk of hemorrhagic complications clearly increased with
prolonged durations of DAPT, and overall 12 months or less
of DAPT was associated with least harm. However, it is not
possible to recommend a more precise duration of therapy
based on current data.
The apparent absence of cardiovascular harmwith shorter
durations was consistently noted in different subgroups strat-
ified by duration of DAPT, individual endpoints, or patient
characteristics. AlthoughGwon et al. [6] suggest that patients
with diabetes mellitus were at significantly higher risk of
myocardial infarction and target vessel revascularization
in the short DAPT group, our subgroup analysis did not
consistently demonstrate any impact of age, presence of
diabetes mellitus, and ACS on the adverse primary outcomes
in both short and long DAPT groups.
Stent thrombosis may have catastrophic consequences
and suboptimal DAPT duration plays an important part [3,
17, 18]. Earlier RCTs during the bare metal stent (BMS) era
[19–21] demonstrated that longer durations of DAPT after
PCI reduced ischemic events.With the increasing use of DES,
several observational studies have reported that early discon-
tinuation of clopidogrel therapy is predictive of stent throm-
bosis [4, 5, 17, 18]. However, none of the studies reported
bleeding complications, so they may provide an unbalanced
6 The Scientific World Journal
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Study or subgroup
3.7.1 3 versus 12 months
Kim et al. 2012
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Gwon et al. 2012
Valgimigli et al. 2012
Subtotal (95% CI)
Total events
Park et al. 2010
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Figure 2: Risk of composite endpoint of death and myocardial infarction.
view of the risk/benefit of DAPT. The current guidelines on
DAPT duration [1, 2, 22] are based on these observational
studies, which means they have inherent limitations.
Ameta-analysis of 22RCTs [23] comparingBMSandDES
showed no difference in risk of acute ischemic events with
DES, and the newer generations of DES have consistently
shown lower rates of late and very late ST [24, 25]. A recent
network meta-analysis has in fact shown that everolimus-
eluting stents (EES) might have lower risk of ST than BMS
within 2 years [26].These findings have supported the notion
that shorter duration of DAPT might be safe and adequate
and this was demonstrated in 2 recent meta-analyses by
Zhang et al. [27] and Ba et al. [28] derived predominantly
from observational studies. The 4 RCTs [6–9] we included
in our study were specifically designed to test this hypothesis
and this makes our meta-analysis more robust.
Our results build upon the findings of the recent meta-
analysis conducted by Cassese et al. [11]. We were able to
include the composite outcome of mortality and myocar-
dial infarction and this gives our study greater power and
subsequently narrower confidence intervals for the pooled
estimate. For instance, Cassese’s meta-analysis focused on
overall mortality as their main endpoint, and the 95%
confidence intervals indicate that they were unable to rule
out a relative increase of 54% in risk of death with shorter
duration of DAPT. Furthermore, we have also performed
subgroup analysis based on patient characteristics, for exam-
ple, younger patients (<65 years), older patients (>65 years),
diabetic patients, and patients with prior acute coronary syn-
drome, and showed that early discontinuation of therapy in
these subgroups did not increase adverse events. In contrast,
Cassese et al. were only able to look at trial characteristics
such as trial size, time of randomization, or publication status.
We are also aware of three other recent articles that cover
this particular topic but are not eligible for inclusion in our
review. Two of these articles were meta-analyses, but their
evaluations appear to be less detailed than the current review
[29, 30]. The other article provided additional data for one of
the trials that was already included, with subgroup analysis
suggesting that there are differences between stents [31].
It is notable that in a few of the analyses there was a
relatively large contribution by the Valgimigli et al. study [9].
This study had a high event rate compared to other studies
as definite or probable stent thrombosis and myocardial
infarction was as high as ∼4% compared to <1% for all
other studies for both outcomes. Possible reasons for the
high event rate may be that the patients had higher baseline
cardiovascular risk, longer follow-up duration, or because
25% of the patients had received bare metal stents.
The studies by Park et al. [8] and Valgimigli et al. [9] used
a landmark analysis design. While this method is employed
to estimate in an unbiased way the time-to-event probability
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Figure 3: Continued.
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Figure 3: Risk of stent thrombosis, myocardial infarction, stroke, and revascularization.
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Figure 4: Continued.
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Figure 4: Risk of mortality and bleeding.
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Figure 5: Risk of adverse primary outcomes in specific subgroups.
for each group assuming the participants aremembers of that
group at the landmark time, this may alter the event rate
compared to other trials. The event rate may be affected by
the choice of landmark time as events that occurred prior
to this would be omitted, which lowers the event rate and
reduces power of the study. However, early landmark may
lead to misclassification at longer follow-up durations.
There are a few important considerations when interpret-
ing the results of this meta-analysis. The results may not be
generalizable to high risk patients such as those with previous
stent thrombosis, those with a large number of stents inserted
or patients in whom there are technical concerns about the
adequacy of stent deployment. Furthermore, while different
drug-eluting stents were used in the trials, our results do not
evaluate whether there are any differences among them. It
is assumed that the randomization process will reduce the
likelihood that the type of stent will give rise to imbalance of
adverse events. In addition, only clopidogrel and aspirin were
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considered as dual antiplatelet therapy and our findings do
not apply to newer agents such as prasugrel and ticagrelor.We
also suggest a cautious interpretation of the results for early
discontinuation of dual antiplatelet therapy (<12 months) in
ACS because of the likely protective effect of dual antiplatelet
therapy on the nonculprit lesions in the coronary circulation.
Our study has several strengths. We only included high
quality randomized controlled trials. We included both
pooled results and results for different cutoffs for discon-
tinuation of antiplatelet therapy. We also considered both
individual outcomes and composite of mortality and MI.
In addition, subgroup analysis was performed to examine
if differences were observed in older and younger patients,
diabetic and nondiabetic patients, and patients with known
prior acute coronary syndrome.
Our study had several limitations. Only four studies were
included in the meta-analysis and these studies had different
definitions of short and long duration of DAPT exposure.
Hence, we are unable tomake definitive recommendations on
the exact duration of DAPT use, although we are reasonably
confident that shorter durations do not necessarily lead to
increased mortality or myocardial infarction in those with
drug-eluting stents.
Secondly, the time of randomization differed in these 4
studies with 2 studies randomized at index PCI (EXCEL-
LENT [6], RESET [7]), 1 study at 1 month after index PCI
(PRODIGY [9]), and the last study at 12 months after index
PCI (REAL/ZEST-LATE [8]). As a result, patients developing
early adverse events (within 30 days and within 6 months,
resp.) in the later 2 studies were excluded. Furthermore, in the
2 former studies, patients with recent myocardial infarction
(<72 hours and <48 hours, resp.) were also excluded. There-
fore, any conclusions derived from pooling these RCTs need
to be interpreted with caution before applying them to the
general cohort of patients in our day-to-day practice.
Thirdly, different generations of DES and a small propor-
tion of BMS (25% of patients in PRODIGY [9]) were used
in the trials included in this analysis. It is possible that there
are significant differences between different types of DES
that cannot be accounted for in this analysis. Furthermore,
current and future innovations in stent design such as
bioabsorbable polymermay allow shorter durations ofDAPT.
Finally, three of the RCTswere conducted amongKoreans
and 1 RCT among Caucasians [6–9] and it is unclear if the
findings are applicable to other countries or ethnic groups.
A recent very small study showed that endothelial function,
which plays an important part in vascular tone, regulating
blood flow, and platelet function, may be lower in Koreans
thanCaucasians [32]. Furthermore, genetic polymorphism of
CYP2C19 was shown to be an independent predictor of clopi-
dogrel resistance in Korean subjects with coronary artery
disease [33]. Although the three Korean studies included low
risk patients, in view of their potential genetic influence on
endothelial function and clopidogrel resistance, more RCTs
involving different populations are pending before we can
make generalized conclusions. The findings of our meta-
analysis should be cautiously interpreted when considering
wider groups of patients in day-to-day clinical practice.
4.1. Suggestions for Future Studies. There are at least four
other RCTs (ISAR-SAFE trial [34], DAPT trial [35], OPTI-
MIZE trial [36]), and OPTIDUAL [37]) ongoing which will
hopefully shedmore light on this challenging topic and guide
clinicians tomake evidence-based decisions for their patients
in the near future. The larger sample sizes will subsequently
allowmore insight into whether certain subgroups of patients
may benefit from longer durations of DAPT.
5. Conclusions
The available evidence from meta-analysis of randomized
controlled trials shows no significant cardiovascular or mor-
tality benefit with longer durations of DAPT as compared to
shorter duration of DAPT. In contrast, a significantly greater
risk of major bleeding was seen with longer durations.
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